Author Archives: Celine

Epcoritamab-bysp and FDA’s Breakthrough Therapy Designation

Posted on by

The FDA just granted Breakthrough Therapy Designation to Epcoritamab-bysp (brand name is Epkinly) for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL).

The decision to grant BTD was supported by the results from the clinical trial NCT03625037, “First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1).
Obtaining Breakthrough Therapy Designation helps facilitate the development of new drugs and treatment options for patients.

Based on the same clinical trial, the FDA approved epcoritamab for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma in May 2023. In the podcast “Oncology Nursing News: The Vitals” Laura Zitella, a nurse at UCSF Health, discusses the newly approved epcoritamab-bysp for DLBCL.

The estimated study completion date of the clinical trial NCT03625037 is April 2024.

Intense Exercise in Lynch Syndrome patients and Cancer Risk

Posted on by

Exercise Oncology Research Program

A new study led by researchers at the University of Texas MD Anderson Cancer Center showed that forty-five minutes of intense exercise three times a week could decrease cancer risk in patients with Lynch Syndrome. Lynch syndrome is a genetic disorder that increases the risk of developing colorectal cancers.

The focus of the study was to investigate how exercising might help prevent cancer. Researchers found that the immune system was boosted in the exercise group, a factor most likely involved in cancer risk reduction.

This study was conducted with a small number of participants (21 patients). Further research is needed to confirm cancer risk reduction in this patient population and explore these findings for the general population.

The study was published in Clinical Cancer Research.

Decrease of Early Breast Cancer Mortality Rates

Posted on by

An observational cohort study led by Dr. Carolyn Taylor from the University of Oxford in the U.K. showed that mortality rates for women diagnosed with early breast cancer in England decreased from a 5-year mortality risk of 14% in the 1990s to 5% in 2010-2015.

Radiology Reading Rooms
Radiology Reading Rooms

The researchers analyzed data from 512,447 women. The study included data from the England National Cancer Registration and Analysis Service between January 1993 and December 2015, with a follow-up until December 2020.

The study’s results might also help providers identify prognostic risk factors for women diagnosed with early breast cancer.
The study was published in BMJ.